Hemagglutinin (ha) Stem - Biotechnology

Relevant Publications

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.

Issue Release: 2024

An explainable language model for antibody specificity prediction using curated influenza hemagglutinin antibodies.

Issue Release: 2024

Stable and efficient generation of functional iPSC-derived neural progenitor cell rosettes through regulation of collective cell-cell behavior.

Issue Release: 2024

rAAV expressing a COBRA-designed influenza hemagglutinin generates a protective and durable adaptive immune response with a single dose.

Issue Release: 2024

Inserting CTL Epitopes of the Viral Nucleoprotein to Improve Immunogenicity and Protective Efficacy of Recombinant Protein against Influenza A Virus.

Issue Release: 2024

C1q enables influenza hemagglutinin stem binding antibodies to block viral attachment and broadens the antibody escape repertoire.

Issue Release: 2024

Ultrapotent influenza hemagglutinin fusion inhibitors developed through SuFEx-enabled high-throughput medicinal chemistry.

Issue Release: 2024

Structural Mapping of Polyclonal IgG Responses to HA After Influenza Virus Vaccination or Infection.

Issue Release: 2024

Site-specific serology unveils cross-reactive monoclonal antibodies targeting influenza A hemagglutinin epitopes.

Issue Release: 2024

Anti-hemagglutinin monomeric nanobody provides prophylactic immunity against H1 subtype influenza A viruses.

Issue Release: 2024

COBRA HA and NA vaccination elicits long-live protective immune responses against pre-pandemic H2, H5, and H7 influenza virus subtypes.

Issue Release: 2024

Rapid synthesis and screening of natively paired antibodies against influenza hemagglutinin stem via oPool display.

Issue Release: 2024

Isolation and characterization of IgG3 glycan-targeting antibodies with exceptional cross-reactivity for diverse viral families.

Issue Release: 2024

Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies.

Issue Release: 2024

Vaccine design via antigen reorientation.

Issue Release: 2024

Structural basis for the broad antigenicity of the computationally optimized influenza hemagglutinin X6.

Issue Release: 2024

Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses.

Issue Release: 2024

Modulating the immunodominance hierarchy of immunoglobulin germline-encoded structural motifs targeting the influenza hemagglutinin stem.

Issue Release: 2024

Protective efficacy of a universal influenza mRNA vaccine against the challenge of H1 and H5 influenza A viruses in mice.

Issue Release: 2023

A broad antibody class engages the influenza virus hemagglutinin head at its stem interface.

Issue Release: 2023

What are the Advantages of Using Viruses?

What Are Some Examples of Biotechnological Applications?

What Regulations Are in Place?

What are the Applications of Recombinant DNA Technology?

How is Genetic Modification Used for Aesthetic Purposes?

What Measures Can Be Taken to Mitigate Ecosystem Disruption?

How Do Corporations Gain Control?

Why are Poplars Important for Genetic Research?

How Do Genetic Markers Aid in Disease Diagnosis?

How is Gene Cloning Regulated?

Partnered Content Networks

Relevant Topics